# EditGene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/editgene

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.edgene.cn
- Total disclosed funding: $1.4M
- Latest round: Angel (Aug 5, 2024)
- Investors on record: 3

## About

Established in 2017 and based in Guangzhou, China, EditGene is a biotechnology company focusing on the development, service and industrialization of CRISPR/Cas gene editing technology. The company was founded by a returning doctors in the field of gene editing technology. Dr. Zhang Xu, the co-founder in charge of technology development, graduated from the University of Munich, Germany. The company has provided CRO services for domestic research institutes and enterprises, and at the same time opened up sales channels in Western Europe, East Asia, North America and other overseas countries and regions. In August 2024, it raised over CNY 10 million in a round of angel funding.

EditGene offers a range of gene editing services and products, including Editx™ gene editing, Bingo™ point mutation, LION™ cellular targeted insertion and FASST nucleic acid rapid detection. Their services extend to CRO services such as gene knockout, gene overexpression, gene mutation, and library screening for research institutes and pharmaceutical companies.

The company generates revenue by providing gene editing services, CRO services, and selling gene editing-related products.

The company will use the angel round of funding to accelerate team building, R&D, product layout, and overseas market development, aiming to expand its services and products in the gene editing industry.

## Funding rounds

- Angel, Aug 5, 2024, $1.4M — Zhongda Venture Capital, Greatwall Fund, Yanghe Biomedicine Industry Investment

## Investors

- Zhongda Venture Capital (https://capitalatlas.ai/funds/zhongda-venture-capital) — Angel
- Greatwall Fund (https://capitalatlas.ai/funds/greatwall-fund) — Angel
- Yanghe Biomedicine Industry Investment (https://capitalatlas.ai/funds/yanghe-biomedicine-industry-investment) — Angel